Polse K A, Brand R J, Keener R J, Schwalbe J S, Vastine D W
Am J Optom Physiol Opt. 1983 Apr;60(4):321-8. doi: 10.1097/00006324-198304000-00011.
The safety of orthokeratological (OK) procedures was assessed by monitoring several ocular characteristics including corneal thickness, refractive astigmatism, corneal astigmatism, correctable spectacle-acuity, corneal edema, corneal staining, and endothelial cell density. Safety was also assessed by reviewing the number and causes of extra clinical visits that occurred because of ocular complications and by determining whether safety factors were related to patients lost to follow-up. Over the 1.2-year period from the baseline examination to the end of the lens-wearing phase of the study, the Treatment (T) and Control (C) groups had, respectively, only small changes in their mean levels of corneal thickness (0.2 vs. 3.2 microns), refractive astigmatism (0.07 vs 0.01 D), and corrected spectacle acuity (0.02 vs 0.018 logarithm of the minimum angle of resolution). Analysis of time trend data obtained from scheduled monthly examinations also showed that changes in mean corneal thickness and mean corneal astigmatism were small and not clinically important in either comparison group during the course of the treatment. As a result of complications from lens wear, the T group required 1.25 times as many extra visits as the C group (p = 0.14). However, none of these visits provided sufficient clinical indication for the discontinuance of lens wear. Loss to follow-up typically occurred because of either poor compliance with the study protocol or loss of motivation caused by minor contact lens-related symptoms such as blurred vision, slight discomfort, or frequently lost lenses. These reasons were similar in both comparison groups. It appears that OK treatment is safe for the types of patients who participated in this study, but it may require more patient monitoring than would be needed to achieve and maintain a physiologically acceptable fit with conventional hard contact lens prescriptions.
通过监测多项眼部特征来评估角膜塑形术(OK)的安全性,这些特征包括角膜厚度、屈光性散光、角膜散光、可矫正的眼镜视力、角膜水肿、角膜染色以及内皮细胞密度。还通过审查因眼部并发症而进行的额外临床就诊次数和原因,以及确定安全因素是否与失访患者有关来评估安全性。在从基线检查到研究镜片佩戴阶段结束的1.2年期间,治疗(T)组和对照组的角膜厚度平均水平(分别为0.2微米和3.2微米)、屈光性散光(分别为0.07 D和0.01 D)以及矫正眼镜视力(分别为0.02和0.018最小分辨角对数)仅有微小变化。对每月定期检查获得的时间趋势数据进行分析还表明,在治疗过程中,两个比较组的角膜厚度均值和角膜散光均值变化都很小,且在临床上并不重要。由于镜片佩戴的并发症,T组需要的额外就诊次数是C组的1.25倍(p = 0.14)。然而,这些就诊均未提供足够的临床指征来停止镜片佩戴。失访通常是由于对研究方案的依从性差,或者是由轻微的隐形眼镜相关症状(如视力模糊、轻微不适或镜片频繁丢失)导致的动力丧失。两个比较组的这些原因相似。看来OK治疗对参与本研究的这类患者是安全的,但与为实现并维持与传统硬性隐形眼镜处方在生理上可接受的适配度相比,可能需要对患者进行更多的监测。